Drug Profile
Letaplimab - Innovent Biologics
Alternative Names: IBI 188Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
- Phase I Solid tumours
- No development reported Lymphoma; Myelodysplastic syndromes
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, First-line therapy, Newly diagnosed) in China (IV, Infusion)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, First-line therapy, Newly diagnosed) in USA (IV, Infusion)
- 16 Feb 2023 Innovent Biologics suspends a phase I/II trial in Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in China (IV) due to changes in development strategies (NCT04485052)